Understanding the role of race in response to hydroxychloroquine treatment in SLE
Understanding the effectiveness of hydroxychloroquine in the real world across specific racial subtypes with Systemic Lupus Erythematosus (SLE).
Leverage OM1 clinical data along with SLEDAI and the OM1 generated eSLEDAI to understand response or differential effect based on race.
- After 3 months of continuous treatment with hydroxychloroquine 7.6% of Caucasians and 7.6% of African Americans experienced a 2 point reduction in SLEDAI.
- After 12 months of continuous treatment with hydroxychloroquine 10.1% of whites and 12.8% of African Americans experienced a 2 point reduction in SLEDAI.
Balanced, representative population with similar response
97.8% of Caucasians and 38.5% African Americans were on systemic treatment at presentation